{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Long-chain+Fatty+Acid+Oxidation+Disorders+%28LC-FAOD%29",
    "query": {
      "condition": "Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 5,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T09:39:54.591Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01886378",
      "title": "A Study of UX007 (Triheptanoin) in Participants With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)",
        "Carnitine Palmitoyltransferase (CPT II) Deficiency",
        "Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency",
        "Longchain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency",
        "Trifunctional Protein (TFP) Deficiency"
      ],
      "interventions": [
        {
          "name": "UX007",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ultragenyx Pharmaceutical Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Months and older"
      },
      "enrollment_count": 29,
      "start_date": "2014-02-06",
      "completion_date": "2016-08-25",
      "has_results": true,
      "last_update_posted_date": "2021-02-11",
      "last_synced_at": "2026-07-23T09:39:54.591Z",
      "location_count": 7,
      "location_summary": "Washington D.C., District of Columbia • Tampa, Florida • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01886378"
    },
    {
      "nct_id": "NCT02214160",
      "title": "Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Extension Study for Subjects Previously Enrolled in Triheptanoin Studies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carnitine Palmitoyltransferase (CPT I or CPT II) Deficiency",
        "Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency",
        "Long-chain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency",
        "Trifunctional Protein (TFP) Deficiency",
        "Carnitine-acylcarnitine Translocase (CACT) Deficiency"
      ],
      "interventions": [
        {
          "name": "UX007",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ultragenyx Pharmaceutical Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Months and older"
      },
      "enrollment_count": 94,
      "start_date": "2014-12-09",
      "completion_date": "2020-12-03",
      "has_results": true,
      "last_update_posted_date": "2023-08-01",
      "last_synced_at": "2026-07-23T09:39:54.591Z",
      "location_count": 9,
      "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Tampa, Florida + 6 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02214160"
    },
    {
      "nct_id": "NCT04812106",
      "title": "Long-Chain Fatty Acid Oxidation Disorders Online Disease Monitoring Program",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)"
      ],
      "interventions": [
        {
          "name": "No Intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Ultragenyx Pharmaceutical Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 8,
      "start_date": "2022-07-25",
      "completion_date": "2022-10-27",
      "has_results": false,
      "last_update_posted_date": "2022-11-18",
      "last_synced_at": "2026-07-23T09:39:54.591Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04812106"
    },
    {
      "nct_id": "NCT04632953",
      "title": "Long-Chain Fatty Acid Oxidation Disorders In-Clinic Disease Monitoring Program",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)"
      ],
      "interventions": [
        {
          "name": "No Intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Ultragenyx Pharmaceutical Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 150,
      "start_date": "2021-11-30",
      "completion_date": "2035-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-03",
      "last_synced_at": "2026-07-23T09:39:54.591Z",
      "location_count": 13,
      "location_summary": "Phoenix, Arizona • San Francisco, California • Aurora, Colorado + 10 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04632953"
    },
    {
      "nct_id": "NCT03768817",
      "title": "Clinical Outcome of Triheptanoin Treatment in Patients With Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) Treated Under Expanded Access Program",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)"
      ],
      "interventions": [
        {
          "name": "No Intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Ultragenyx Pharmaceutical Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 20,
      "start_date": "2019-01-30",
      "completion_date": "2020-06-08",
      "has_results": false,
      "last_update_posted_date": "2020-08-28",
      "last_synced_at": "2026-07-23T09:39:54.591Z",
      "location_count": 15,
      "location_summary": "Los Angeles, California • Orange, California • Palo Alto, California + 11 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03768817"
    }
  ]
}